Related by context. All words. (Click for frequent words.) 75 oral prodrug 74 Aurora Kinase 74 ENMD # 74 CYT# potent vascular disrupting 74 Personalized Immunotherapy 74 pathophysiological effects 73 kidney urologic 73 selective modulator 73 antisense inhibitors 73 fosbretabulin 73 CCX# 72 receptor tyrosine kinase inhibitor 72 MCSP respectively 72 Symadex 72 EGFR HER2 72 Granulocyte Colony Stimulating Factor 72 novel VDA molecule 72 Presents Preclinical Data 72 preclinically 72 protein tyrosine phosphatase 1B 72 vidofludimus 72 orally administered inhibitor 72 JAK inhibitors 71 CD# CEA 71 AAG geldanamycin analog 71 INCB# [001] 71 A3 adenosine receptor 71 alvespimycin 71 Aviptadil 71 Pafuramidine 71 selective kinase inhibitor 71 Gleevec resistant 71 demonstrated antitumor activity 71 Tezampanel 71 HCV protease 71 Recombinant Human 71 Initiates Clinical 71 LHRH antagonists 71 HGS ETR2 70 oral picoplatin 70 HER2 overexpression 70 K ras mutations 70 Epidermal Growth Factor Receptor 70 Hsp# Inhibitor 70 Panzem 70 anti amnesic 70 metaglidasen 70 forodesine 70 CTAP# Capsules 70 Immunotherapeutic 70 Panzem R 70 riociguat 70 ONCONASE R 70 CCR5 mAb 70 thalidomide Thalomid 70 tubulin inhibitor 70 Solazed TM 70 RNAi Therapeutic 70 HCV protease inhibitors 70 receptor inhibitor 70 c MET 70 Systemic Delivery 70 Virulizin ® 70 TTR gene 70 Tyrosine Kinase Inhibitor 70 XL# inhibits 70 Kinase Inhibitor 70 beta 1a 70 Factor Receptor 70 xenograft models 70 TBC# 70 OMP #M# 70 pharmacokinetic interactions 70 CBLC# 70 MAGE A3 ASCI 70 CCR9 70 MEK inhibitors 70 novel therapeutic antibodies 70 Meets Primary Endpoint 69 vivo validation 69 ALN TTR 69 acetonide FA 69 Blinatumomab 69 chemokine receptors 69 telomerase therapeutic 69 Rigel R# 69 CCR9 antagonist 69 Safinamide 69 Completes Patient Enrollment 69 FLT3 69 including eniluracil ADH 69 immuno modulatory 69 PEG SN# 69 HQK 69 immune modulating 69 Factor VIIa 69 HGS ETR1 mapatumumab 69 pan HDAC inhibitor 69 Archexin 69 nucleoside analog 69 ALN PCS 69 epigenetic therapies 69 Xanafide 69 alpha#beta# integrin 69 Initiates Enrollment 69 Reports Preclinical Data 69 LymphoStat B belimumab 69 THR beta agonist 69 vascular disrupting agents 69 chemokine receptor 69 p# inhibitor 69 HCD# [002] 69 mGluR2 NAM 69 HCV polymerase 69 Enzastaurin 69 mGluR5 NAM 69 Telbivudine 69 MGd 69 Initiates Phase II 69 therapeutic monoclonal antibody 69 HGF c Met 69 MET amplification 69 TNF alpha selectively neutralizing 69 myelofibrosis polycythemia vera 69 relapsed MM 69 #ME# 69 EGFr 69 Sym# 69 highly selective inhibitor 69 R roscovitine 69 non nucleoside HCV 69 preclinical efficacy 69 effector function 69 glucagon receptor 69 IMA# 69 MKC# MT 69 immunomodulatory 69 PDE# inhibitors 69 anti CD3 69 RGB # 69 Interferon alpha 69 potent suppressor 69 Tß4 69 interleukin IL -# 69 Antitumor Activity 69 Thiovir 69 VEGF inhibitors 69 CYP#A# CYP#D# 69 Sapacitabine 69 PDE# 69 GRN# 69 OMP #R# 69 pharmacodynamic parameters 68 Phase 2b Clinical Trial 68 p# alpha [001] 68 Angiotensin converting enzyme 68 inducible nitric oxide synthase 68 NS#/#A protease 68 Anti Tumor 68 OXi# 68 Inhalation Solution 68 cyclooxygenase 2 68 Antitumor 68 Preclinical Study 68 Achieves Primary Endpoint 68 immune stimulatory 68 oral JAK1 68 PDGFR 68 mda 7 68 SYN# 68 Protein Kinase C 68 Onconase 68 JAK3 68 tramiprosate Alzhemed TM 68 SPRYCEL ® 68 IAP inhibitor 68 Drug Candidate 68 Romidepsin 68 Seliciclib 68 cannabinor 68 Deforolimus 68 Interferon Beta 68 gastrointestinal stromal tumors GISTs 68 TLR8 68 sorafenib tablets 68 YONDELIS 68 AT1R 68 Sudhir Agrawal D.Phil 68 IGF IR 68 TRAIL receptor antibodies 68 potently inhibit 68 Aflibercept 68 MEK Inhibitor 68 mTOR mammalian target 68 FOLOTYN ® 68 Begins Dosing 68 CCR1 68 Zoraxel 68 rxRNA 68 Aurora kinase 68 hypereosinophilic syndrome 68 Th2 cytokines 68 R#/MEM # 68 Omacetaxine 68 XL# anticancer compounds 68 TNFalpha 68 JAK2 Inhibitor 68 Exherin TM 68 T#I [002] 68 mTOR kinase 68 mTOR inhibition 68 SAR# [002] 68 trastuzumab Herceptin R 68 TRAIL R2 68 #beta HSD1 68 Phase 2a Clinical Trial 68 investigational therapies 68 Initiate Clinical Trial 68 MEK inhibitor 68 JAK2 inhibitor 68 Initiates Clinical Trial 68 5 HT6 receptor 68 antiproliferative effects 68 thiazolides 68 PXD# 68 BRAF inhibitor 68 immunomodulation 68 investigational humanized monoclonal antibody 68 myeloproliferative diseases 68 TTR amyloidosis 68 liposomal formulation 68 TNFa 68 splice variants 68 RhuDex R 68 ZFP Therapeutics 68 AEG# 68 OvaRex R 68 galiximab 68 lintuzumab SGN 68 Triapine R 68 Nanobody ® 68 PIGF 68 JAK Inhibitor 68 myeloproliferative disorders 68 EGFR pathway 68 Lenocta 68 SIRT1 activators 68 Multimeric 68 CORT # 68 Initiates Phase III 68 radezolid 68 Epothilones 68 anti fibrotic 68 aurora kinase 68 DNA methyltransferase inhibitors 68 molecular biomarkers 68 CDK inhibitor 68 Vicriviroc 68 fusion enhancers 68 Vidaza azacitidine 67 interferon IFN 67 siRNA therapeutics 67 Talabostat 67 Dendritic Cells 67 Pimavanserin 67 Talactoferrin 67 K RAS 67 PDGF receptor 67 monocytes macrophages 67 TKM ApoB 67 PKC# 67 urocortin 2 67 sodium thiosulfate STS 67 GMX# 67 p# biomarker 67 RNAi therapeutic targeting 67 Dasatinib 67 TRIOLEX HE# APOPTONE HE# 67 ON #.Na 67 tumor antigen 67 DXL# 67 gefitinib Iressa 67 PDE4 inhibitor 67 imatinib Gleevec ® 67 GSK3B 67 SNT MC# 67 Pivotal Phase III 67 mertansine 67 evaluating tivozanib 67 CG# [003] 67 Evoltra ® 67 TRO# 67 LPA1 receptor 67 ATL# [001] 67 EGFR tyrosine kinase inhibitors 67 Cetrorelix 67 hypoxia activated prodrug 67 erlotinib Tarceva ® 67 investigational monoclonal antibody 67 immune modulatory 67 tumorigenicity 67 MKC# MKC# PP 67 zanolimumab 67 CA4P 67 Prodarsan ® 67 Pegylated 67 JAK1 67 Tasimelteon 67 Golimumab 67 tumor necrosis 67 telomerase inhibitor 67 Afatinib 67 R Saizen R 67 immunomodulatory properties 67 PhG alpha 1 67 sarcoma melanoma 67 Flt3 67 antiangiogenic agents 67 virus HCV protease inhibitor 67 CXCR7 67 E#F# 67 orally inhaled migraine 67 alpha folate receptor 67 DCCR 67 NS5b 67 pharmacodynamic markers 67 Clusterin 67 Presents Preclinical 67 RNA antagonist 67 Preclinical Data 67 selective inhibition 67 systemically administered 67 Prodarsan R 67 flavopiridol 67 Severe Sepsis 67 metastatic neuroendocrine tumors 67 histone deacetylase inhibitor 67 NF kB pathway 67 humanised monoclonal antibody 67 mediated inhibition 67 Aliskiren 67 Hsp# inhibition 67 oral ghrelin agonist 67 Glufosfamide 67 neurotrophic 67 ganetespib 67 TLK# 67 huC# DM4 67 Aganocide 67 S/GSK# 67 phosphate S1P 67 EDEMA3 trial 67 oral salmon calcitonin 67 proteasome inhibitor 67 Gag polymorphisms 67 antisense compounds 67 Investigational Compound 67 Cardiotoxicity 67 TÎ ² 4 67 hypoxia inducible factor 67 Nanobodies ® 67 histone deacetylase HDAC 67 itraconazole Sporanox 67 JAK2 kinase 67 Ozarelix 67 non nucleoside inhibitor 67 PNP inhibitor 67 NOX E# 67 Darinaparsin 67 Phase 1b clinical trials 67 small molecule activators 67 vinca alkaloid 67 nalbuphine ER 67 Novel Oral 67 anionic backbone 67 Capesaris 67 Ceflatonin 67 RhuDex ® 67 Belimumab 67 Ocrelizumab 67 agonists antagonists 67 targeting PCSK9 67 Squalamine 67 PROSTVAC VF 67 TransVax ™ 67 docetaxel Taxotere ® 67 orally dosed 67 midstage clinical 67 antimitotic 67 ESBA# 67 Panzem R NCD 67 erythropoietic 67 candidates Azedra TM 67 p# activation 67 JAK2 enzyme 67 castrate resistant prostate cancer 67 Hypercholesterolemia 67 Monoclonal Antibody 67 VIPR2 67 tumor xenograft models 67 Vaccine Adjuvant 67 immunomodulatory therapy 67 R lenalidomide 67 targeting CD# 67 Receives Orphan Drug 67 polymerase inhibitors 67 Preclinical Models 67 Maribavir 67 Phase III Pivotal 67 HER1 67 Oral Fingolimod 67 Homspera TM 67 HuLuc# 67 Elagolix 67 oncolytic virus therapies 67 FGFR 67 biologic therapeutics 67 ATTR CM 67 PSN# [002] 67 GW# [003] 67 ARIKACE ™ 67 cytomegalovirus CMV 67 antiangiogenic activity 67 Preclinical studies suggest 67 EGFR tyrosine kinase inhibitor 67 tiapamil 67 TKM PLK1 67 PSMA ADC 67 HIF PH inhibitors 67 Muraglitazar 67 Zemiva TM 67 pharmacokinetic PK study 67 acadesine 67 novel peptide 67 adipogenic 67 PRTX 67 Epratuzumab 66 Tumor Necrosis Factor 66 alkylating agent 66 HIF 1alpha 66 rhIL 7 66 trastuzumab Herceptin ® 66 transgenic rats 66 Mutational 66 PC# cells 66 Akt activation 66 Entereg R 66 immunotherapeutic vaccine 66 Posiphen 66 Vidofludimus 66 systemic RNAi therapeutic 66 LymphoStat B TM 66 PIK3CA 66 targeted radiotherapeutic 66 thymidylate synthase TS 66 Pegloticase 66 GRNCM1 66 Traficet EN 66 pro angiogenic 66 OMNARIS HFA 66 APOPTONE 66 LPA1 66 CB2 receptor 66 Temsirolimus 66 TLR9 agonist 66 includes TOLAMBA TM 66 RANK Ligand 66 refractory metastatic 66 Lixivaptan 66 neuronal nitric oxide synthase 66 cathepsins 66 nucleotide analog 66 vivo potency 66 Files IND 66 LHRH receptor positive 66 uricase 66 Vidaza ® 66 PEGylated Fab fragment 66 small molecule thrombopoietin 66 enzastaurin 66 somatostatin 66 TRX1 66 AKT inhibitor 66 NS5A 66 elotuzumab 66 systemic fungal infections 66 ERK signaling 66 Cloretazine 66 RAV# 66 isoform selective 66 PI3K/mTOR 66 ASONEP 66 Cytochrome P# 66 Receives Orphan Drug Designation 66 HER2 expression 66 UPLYSO 66 multikinase inhibitor 66 DNA methyltransferases 66 CEQ# 66 Protexia ® 66 Actimmune ® 66 PEGylated interferon 66 CYC# 66 antibody MAb 66 nonclinical studies 66 ALK inhibitors 66 Trofex TM 66 canakinumab 66 protein kinase inhibitor 66 TNF Tumor Necrosis Factor 66 Fc receptor 66 SERMs 66 Locked Nucleic Acid LNA 66 cediranib 66 Aplidin 66 P#X# 66 CanAg 66 BCR ABL inhibitors 66 formerly LymphoStat B 66 PI3K inhibitor 66 HuMax TAC 66 γ secretase 66 TRAIL induced apoptosis 66 ddRNAi 66 cleavable linker 66 Annamycin 66 C5aR 66 novel anticancer 66 mTOR inhibitors 66 dasatinib Sprycel 66 GPx 66 Prolongs Survival 66 potent antiproliferative 66 Trandolapril 66 XmAb# 66 Akt inhibitor 66 recurrent metastatic ovarian cancer 66 Lisofylline 66 immunotherapeutic approaches 66 IL 1β 66 GRNVAC1 66 oral nucleoside analogue 66 Tolvaptan 66 Present Preclinical Data 66 RRM1 66 Angiolix 66 oral proteasome inhibitor 66 MAPK pathway 66 Tigecycline 66 myelodysplastic myeloproliferative diseases 66 TLR antagonists 66 prasterone 66 IFN γ 66 ERK1 2 66 Phase #b/#a clinical 66 chimeric monoclonal antibody 66 Exelixis XL# 66 generation antisense inhibitor 66 Hedgehog Pathway Inhibitor 66 Vorinostat 66 Interferon Gamma 66 ospemifene 66 experimental autoimmune encephalomyelitis 66 adalimumab Humira 66 inverse agonist 66 bortezomib Velcade 66 Antibody Drug Conjugate 66 p# MAP kinase inhibitor 66 Zorbtive TM 66 Thiarabine 66 anticancer activity 66 Gefitinib 66 lymphoid malignancies 66 gastric carcinogenesis 66 antitumor effects 66 Demonstrates Efficacy 66 AGTR1 66 Pazopanib 66 ZOLINZA 66 cytochrome P 66 E1 INT TM 66 Pathway Inhibitor 66 visilizumab 66 CCR2 66 Carfilzomib 66 Elotuzumab 66 TELINTRA 66 Aplidin R 66 IFN beta 66 ZYBRESTAT fosbretabulin 66 Phase 2b Trial 66 Beta catenin pathway 66 Fulvestrant 66 ARRY # 66 Aeolus Pharmaceuticals Announces 66 cAMP signaling 66 tezampanel 66 hyperphenylalaninemia HPA due 66 leukocyte adhesion 66 radiation sensitizer 66 dimebon latrepirdine 66 sJIA 66 peripherally acting 66 CINTREDEKIN BESUDOTOX 66 topoisomerase II inhibitor 66 pancreatic prostate 66 Eculizumab 66 ATL/TV# 66 IgG1 antibodies 66 haematological malignancies 66 Azedra 66 Demonstrates Positive 66 specific lectin receptors 66 Liprotamase 66 KRAS oncogene 66 Xcytrin R 66 potently inhibited 66 cobiprostone 66 delafloxacin 66 multitargeted 66 Bafetinib 66 p#INK#a 66 agonistic human 66 systemic RNAi 66 Tarceva TM 66 humanized monoclonal 66 prognostic markers 66 Fabry Disease 66 plasma kallikrein inhibitor 66 non nucleoside 66 pharmacogenomic translational research 66 neuroprotective properties 66 platform HDL Mimetic 66 Selective Electrochemical Tumor Ablation 66 HER2/neu 66 NMDA antagonists 66 GVAX ® 66 hematological parameters 66 davunetide intranasal AL 66 potent anti angiogenic 66 Prestara 66 EGFR HER 66 gastrin 66 Valortim R 66 androgen receptor AR 66 torezolid phosphate 66 IMiDs ® 66 ALK inhibitor 66 ORENCIA R 66 indinavir Crixivan 66 rBChE 66 Phase III Clinical Trial 66 NEUGENE 66 Bucindolol 66 dasatinib Sprycel ® 66 Tarvacin TM 66 Maxy G# 66 Microplasmin 66 IFN α 66 small molecule agonists 66 Treg cell 66 bFGF 66 heparanase 66 catheter occlusion 66 epithelial tumors 65 ABCB1 65 gastro intestinal inflammation 65 Kinase Inhibitors 65 nucleoside analogues 65 CRLX# 65 IL# PE#QQR 65 imatinib Gleevec 65 trastuzumab DM1 T DM1 65 IL 1ß 65 clevidipine 65 DiLA2 liposomes 65 Methylnaltrexone 65 SAR# [004] 65 biased ligand 65 nilotinib Tasigna ® 65 DermaVir 65 FGFR2 65 Chronic Lymphocytic Leukemia CLL 65 KRAS mutant 65 Guanilib 65 Trofex 65 uric acid lowering 65 Teriflunomide 65 Th1 type 65 fibrotic disease 65 Fibroblast 65 circulating endothelial cells 65 2 methoxyestradiol 65 Triapine 65 glucokinase activator 65 polyglutamate 65 hyaluronidase enzyme 65 Universal Flu Vaccine 65 endogenous ligands 65 cyclin E 65 IMC #B 65 CEACAM1 65 inhibit metastasis 65 atacicept 65 small molecule tyrosine 65 BCG refractory carcinoma 65 solithromycin 65 cilengitide 65 multi kinase inhibitor 65 Iloperidone 65 HMG CoA reductase inhibitors 65 Cathepsin B 65 INCB# [003] 65 Exelixis compounds 65 Raf kinase 65 Civacir 65 Sphingomab 65 HGS ETR1 65 pDCs 65 potent antitumor activity 65 direct thrombin inhibitors 65 ADAMTS# 65 HIF 1α 65 immunotoxin 65 mGluR2 65 TLE3 65 Orally administered 65 TO AVOID PREGNANCY WHILE 65 vascular disrupting agent 65 bevacizumab Avastin ® 65 Kamada AAT 65 tryptase 65 Fc fusion protein 65 cMET inhibitor 65 MEK inhibitor RDEA# 65 potent inhibitors 65 2 inhibitor CYT# 65 Angiocept 65 Naive Patients 65 endothelin receptor 65 Hematologic 65 GATTEX TM 65 aripiprazole Abilify 65 FOLFOX6 chemotherapy regimen 65 Elvitegravir 65 oral dnaJP1 65 triphendiol 65 depsipeptide 65 sodium glucose cotransporter 65 antiapoptotic 65 Pertuzumab 65 IGFBP2 65 Kinases 65 Antithrombin 65 NS5B polymerase 65 PEGylated anti 65 eTag assays 65 decitabine 65 azilsartan medoxomil 65 albiglutide 65 Degarelix 65 Serostim ® 65 VEGFR1 65 molecular imaging radiopharmaceutical 65 Zybrestat 65 antiangiogenic 65 antisense inhibition 65 refractory chronic lymphocytic 65 vapreotide acetate 65 TACI Ig 65 Combination REOLYSIN R 65 Announces Poster Presentations 65 Hepatocellular Carcinoma HCC 65 midstage trials 65 peroxisome proliferator activated 65 severe hypersensitivity reactions 65 humanized monoclonal antibodies 65 GAMMAGARD 65 Phase IIb Trial 65 Novel Therapeutic 65 LRP5 65 Fondaparinux 65 hedgehog pathway 65 familial amyloidotic polyneuropathy FAP 65 Cannabinor 65 hA# 65 Estrogen Receptor 65 JUVISTA R Human 65 ImmunoVEX HSV2 65 NPC 1C 65 Randomized Phase 65 adenoviral vectors 65 favorable pharmacokinetic profile 65 Azedra TM 65 Dapagliflozin 65 PRT# 65 HGS# 65 VEGFR2 inhibitor 65 taxane resistant 65 Thalomid ® 65 Phase #b/#a trial 65 IMiDs ® compound 65 Nanobody R 65 tarenflurbil 65 V#F mutation 65 Fludara ® 65 Xelox 65 mGlu2 3 65 CENP E 65 RAF kinase VEGFR 65 Phase IIb III 65 Myelodysplastic Syndrome MDS 65 Hepatocytes 65 Anthracycline 65 prokinetic agent 65 IAP inhibitors 65 5 HT2A serotonin 65 eIF 4E 65 Cethromycin 65 anti inflammatory cytokine 65 antitumor efficacy 65 Mipomersen 65 mapatumumab 65 Cytotoxic T 65 Raf MEK ERK 65 HTS assay 65 multiple sclerosis psoriasis 65 estrogen receptor beta 65 CIMZIA ™ 65 Tasigna prolongs 65 EGF receptor 65 CINQUIL 65 acyclovir Lauriad R 65 lucinactant 65 busulfan 65 elvucitabine 65 huN# DM1 65 Humanized Anti 65 PHX# 65 Triolex 65 GFT# 65 TLR9 agonists 65 2A receptor agonist 65 Clinical Trial Results 65 Corgentin 65 somatostatin analog 65 TRANSDUR ® 65 Tamibarotene 65 GTC recombinant human 65 K ras 65 Nanobody 65 Epstein Barr Virus EBV 65 ocular formulation 65 prostanoid 65 RNAi Therapeutics 65 Marqibo TM 65 neuronal nicotinic receptor NNR 65 tanespimycin 65 antiangiogenesis 65 HIV coinfected 65 TIMP 1 65 PI3K Akt 65 MAGE A3 65 FGFs 65 cytostatic 65 plasma kallikrein 65 Ridaforolimus 65 INT# [002] 65 granzyme B 65 lenalidomide dexamethasone 65 Hepatotoxicity 65 Valortim ® 65 refractory gout 65 Granted Orphan Drug 65 R#/MEM 65 Nitazoxanide 65 synthetic retinoid 65 MOVIPREP R 65 LEP ETU 65 #D#C# 65 Interferon beta 65 HSP# inhibitor 65 Chemokine Receptor 65 BRAF V#E mutation 65 soluble tumor necrosis 65 Denufosol 65 lumiliximab 65 UGT#A# 65 Dalbavancin 65 SERCA2a 65 TKB# 65 Anidulafungin 65 factor VIIa 65 Pradefovir 65 Tie2 65 c MYC 65 Gastrointestinal Stromal Tumors 65 Allovectin 7 R 65 hENT1 65 vitro assay 65 isotypes 65 Phase III Clinical Trials 65 CYP#C# [002] 65 Fluvastatin 65 vivo pharmacology 65 EZN 65 Atypical Hemolytic Uremic Syndrome 65 PNT# 65 miR #a [001] 65 Investigational Treatment 65 Successfully Completes Phase 65 IGFBP 3 65 Nilotinib 65 Anticalins ® 65 sitaxsentan 65 dopamine D2 65 potent anticancer 65 Tyrima 65 Telik logo TELINTRA 65 CRAC channel 65 budesonide foam 65 BZL# 65 TLR9 65 Arimoclomol 65 trodusquemine 65 predictive biomarker 65 chemopreventive agent 65 paclitaxel cisplatin 65 adenosine A2A 65 Metastatic Melanoma 65 Ceflatonin R 65 Rebif ® 65 candidate CRLX# 65 pomalidomide 65 sunitinib Sutent 65 Bendavia 65 CR# vcMMAE 65 kinase inhibition 65 Spiegelmer ® 65 FGFR1 65 leukotriene pathway 65 intranasal formulation 65 ulimorelin 65 tezampanel NGX# 65 XL# XL# 65 essential thrombocythemia ET 65 Janus kinase 65 compound AEZS 65 Azacitidine 65 potent cytotoxic 65 polymerase inhibitor 65 recurrent glioblastoma multiforme 65 Patients Treated With 65 YONDELIS R 65 GERD migraine headaches 65 Proellex TM 65 vitro pharmacology 65 Phase IIb Clinical Trial 65 Lisofylline LSF 65 JAK2 65 chronic eosinophilic leukemia 65 neurite outgrowth 65 abnormal p# 65 hematological indications 65 investigational protease inhibitor 65 PEGylated interferon beta 1a 65 endothelin receptor antagonists 65 Solorel TM 65 IL #E 65 pralatrexate injection folate analogue 65 PLK1 SNALP 65 IMiDs R 65 CIMZIA TM 65 BHT DNA 65 E selectin 65 HCV replicon 65 ThermoDox ® clinical 65 factor TNF receptor 65 EP #R 65 zileuton 65 Silodosin 65 gamma secretase inhibitor 65 CMV vaccine 65 selective estrogen receptor modulator 65 RAS RAF MEK 65 HuMax EGFr 65 Neulasta ® 65 ZFN modified 65 Genentech Rituxan 65 ritonavir boosted 65 inflammatory autoimmune diseases 65 metastatic colorectal 65 IL 1Ra 65 ERK pathway 65 Romiplostim 65 Immunomodulatory 65 Galectin 3 65 PI3K/Akt pathway inhibitor 65 antagomirs